- Home
- ICLR vs MBLY Comparison
ICLR vs MBLY Comparison
Compare ICLR & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | MBLY |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 9.1B |
| IPO Year | 2001 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ICLR | MBLY |
|---|---|---|
| Price | $146.18 | $9.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 20 |
| Target Price | ★ $178.62 | $14.13 |
| AVG Volume (30 Days) | 1.1M | ★ 5.4M |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,894,000,000.00 |
| Revenue This Year | N/A | $4.91 |
| Revenue Next Year | N/A | $13.94 |
| P/E Ratio | $12.91 | ★ N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $66.57 | $6.47 |
| 52 Week High | $211.00 | $20.18 |
Technical Indicators
Market Signals| Indicator | ICLR | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 63.32 | 47.71 |
| Support Level | $99.11 | $8.43 |
| Resistance Level | $188.03 | $9.62 |
| Average True Range (ATR) | 8.29 | 0.53 |
| MACD | 1.04 | -0.18 |
| Stochastic Oscillator | 77.73 | 18.90 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.